Successful Treatment of Necrotizing Retinitis with Epstein–Barr Virus-Positive Ocular Fluid by Intravitreal Methotrexate Injection. (18th May 2020)

• Record Type: Journal Article
• Authors: Mashima, Asako; Usui, Yoshihiko; Umazume, Kazuhiko; Muramatsu, Daisuke; Goto, Hiroshi
• Is Part Of: Ocular immunology and inflammation. Volume 28:Number 4(2020)
• Page Start: 552
• Page End: 555
• Publication Date: 2020-05-18
• Subjects: Epstein–Barr -- virus -- intravitreal -- methotrexate -- injection -- necrotizing retinitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1609047
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To present a case of necrotizing retinitis with Epstein–Barr virus (EBV)-positive ocular fluid in a patient with sudden unilateral vision loss, which was successfully treated with intravitreal methotrexate (MTX) injections. Methods: Retrospective case report. Results: An 83-year-old female who had been on methylprednisolone for 20 years due to interstitial pneumonia developed vitreous opacity and extensive necrotizing retinitis with retinal hemorrhage sparing the posterior pole in the left eye. Multiplex polymerase chain reaction (PCR) for viral DNA using vitreous sample was positive for EBV but negative for herpes simplex virus, varicella-zoster virus, and cytomegalovirus. Real-time PCR detected EBV-DNA in aqueous humor but not in peripheral blood sample. Serologic testing was negative for Toxoplasma gondii, syphilis, and HIV. The patient did not respond to systemic ganciclovir or acyclovir. Subsequent treatment with intravitreal MTX resulted in immediate clinical improvement correlating with a decrease in copy number of EBV-DNA. Conclusion: Intravitreal MTX may be an effective treatment option for patients with necrotizing retinitis and EBV-positive ocular fluid not responding to conventional antiviral therapy.